Abbisko Cayman Limited
2256
Rank in Stocks
#11366
Founded in 2016 and headquartered in Shanghai, People's Republic of China,... Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Share Price
$0.79759653
Last synced: 2026-11-10
Market Cap
$572.67M
Change (1 day)
-0.71%
Change (1 year)
-56.11%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Abbisko Cayman Limited (2256)
Category
Healthcare
Operating Margin for Abbisko Cayman Limited (2256)
Operating Margin as of November 2026 TTM: -532.67%
According to Abbisko Cayman Limited's latest financial reports, its current operating margin (TTM) is -532.67%. At the end of 2025 the company had an operating margin of 4.56%.
Operating Margin history for Abbisko Cayman Limited from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -532.67% | -11,781.36% |
| 2025 | 4.56% | -206.54% |
| 2024 | -4.28% | -99.84% |
| 2023 | -2,681.41% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -1,447.05% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -3,495.78% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.07% |
US
|
|
| -149.01% | -99.72% |
US
|
|
| 25.57% | -100.05% |
AU
|
|
| 31.23% | -100.06% |
BE
|
|
| 29.35% | -100.06% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Abbisko Cayman Limited's operating margin
What is Abbisko Cayman Limited's operating margin?
Abbisko Cayman Limited's operating margin is -532.67%, as of Nov 2026.
What was Abbisko Cayman Limited's operating margin in 2025?
In 2025, Abbisko Cayman Limited's operating margin was 4.56%, compared with -4.28% in 2024.
How has Abbisko Cayman Limited's operating margin changed since 2020?
From 2020 to 2025, Abbisko Cayman Limited's operating margin was highest in 2025 (4.56%) and lowest in 2023 (-2,681.41%).
How does Abbisko Cayman Limited's operating margin compare with similar companies?
Abbisko Cayman Limited's operating margin (-532.67%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.